Faeth Therapeutics is pioneering multi-node inhibition of the PAM (PI3K/AKT/mTOR) pathway — the most frequently altered oncogenic pathway in cancer. Our lead candidate PIKTOR is an all-oral combination that is designed to achieve deeper pathway suppression with greater tolerability by targeting multiple nodes simultaneously.
Calendar
–
View all events & presentations
Events.
Latest
–
View all news
News and updates.
Aug 07 2026
Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AUSTIN, Texas --(BUSINESS WIRE)--Aug. 7, 2026-- Faeth Therapeutics, Inc. (Nasdaq: FTH) today announced that the Compensation Committee of Faeth’s Board of Directors granted two new employees options to purchase an aggregate of 11,000 shares of the Company’s common stock in connection with their
Read More
Aug 07 2026
Faeth Therapeutics to Present PK/PD Modeling That Informed PIKTOR Dose Selection in Ongoing FTH-PIK-201 Trial at Upcoming Scientific Conference
— The data will be presented at the 2026 Summit for Novel Therapeutics in Oncology and Precision Medicine in Cancer conference on August 8 — These data collectively informed PIKTOR dose selection in the ongoing Phase 2 trial in second-line advanced endometrial cancer (Study FTH-PIK-201) AUSTIN,
Read More
Aug 04 2026
Faeth Therapeutics Reports Second Quarter 2026 Financial Results and Operational Updates
— Topline results from the Phase 2 PIK-201 trial in endometrial cancer on track for year-end — First patient dosed in the Phase 1b/2 PIK-101 trial in HR+ breast cancer — Company changed name to Faeth Therapeutics, Inc. on June 15, 2026; common stock began trading under the ticker symbol “FTH” on
Read More
Jul 23 2026
Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AUSTIN, Texas --(BUSINESS WIRE)--Jul. 23, 2026-- Faeth Therapeutics, Inc. (Nasdaq: FTH) today announced that the Compensation Committee of Faeth’s Board of Directors granted two new employees options to purchase an aggregate of 25,500 shares of the Company’s common stock in connection with their
Read More
Jul 03 2026
Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AUSTIN, Texas--( BUSINESS WIRE)--Faeth Therapeutics, Inc. (Nasdaq: FTH) today announced that the Compensation Committee of Faeth’s Board of Directors granted six new employees options to purchase an aggregate of 180,350 shares of the Company’s common stock in connection with their employment